Vitamin D inhibits development of liver fibrosis in an animal model but cannot ameliorate established cirrhosis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 308, Issue 2, 2015, Pages G112-G120

  Abramovitch, Shirley ^a   Sharvit, Efrat ^b   Weisman, Yosef ^c   Bentov, Amir ^c   Brazowski, Eli ^c   Cohen, Gili ^a   Volovelsky, Oded ^a   Reif, Shimon ^a,d  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Collagen; Fibrosis; Liver; Thioacetamide; Vitamin D

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; PLATELET DERIVED GROWTH FACTOR; THIOACETAMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BILE DUCT LIGATION; CHEMOLUMINESCENCE; CONTROLLED STUDY; HYPERCALCEMIA; IN VITRO STUDY; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; CELL PROLIFERATION; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL LIVER CIRRHOSIS; FIBROSIS; METABOLISM; PATHOLOGY; STELLATE CELL; WISTAR RAT;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FIBROSIS; HEPATIC STELLATE CELLS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; RATS, WISTAR; THIOACETAMIDE; VITAMIN D;

EID: 84921497292     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00132.2013     Document Type: Article

References (29)

1. Abramovitch S, Dahan-Bachar L, Sharvit E, Weisman Y, Ben Tov A, Brazowski E, Reif S. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut 60: 1728–1737, 2011.
2. Artaza JN, Norris KC. Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. J Endocrinol 200: 207–221, 2009.
3. Artaza JN, Sirad F, Ferrini MG, Norris KC. 1,25(OH)2vitamin D3 inhibits cell proliferation by promoting cell cycle arrest without inducing apoptosis and modifies cell morphology of mesenchymal multipotent cells. J Steroid Biochem Mol Biol 119: 73–83, 2010.
4. Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 55: 2624–2628, 2010.
5. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 115: 209–218, 2005.
6. Batts KP, Ludwig J. Chronic hepatitis: an update on terminology and reporting. Am J Surg Pathol 19: 1409–1417, 1995.
7. Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, de Franchis R, Almasio PL, Maisonneuve P. Sustained virologic response prevents the development of esophageal varices in compensated, child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 51: 2069–2076, 2010.
8. Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, Leblanc M, Coulter S, He M, Scott C, Lau SL, Atkins AR, Barish GD, Gunton JE, Liddle C, Downes M, Evans RM. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 153: 601–613, 2013.
9. Friedman SL. Liver fibrosis: from bench to bedside. J Hepatol 38, Suppl 1: S38–S53, 2003.
10. Gal-Tanamy M, Bachmetov L, Ravid A, Koren R, Erman A, Tur-Kaspa R, Zemel R. Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology 54: 1570–1579, 2011.
11. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348: 800–807, 2003.
12. Hirose M, Nishino T, Obata Y, Nakazawa Y, Nakazawa Y, Furusu A, Abe K, Miyazaki M, Koji T, Kohno S. 22-Oxacalcitriol prevents progression of peritoneal fibrosis in a mouse model. Perit Dial Int 33: 132–142, 2012.
13. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 65: 305–311, 1984.
14. Kumar R, Nagubandi S, Mattox VR, Londowski JM. Entero-hepatic physiology of 1,25-dihydroxyvitamin D3. J Clin Invest 65: 277–284, 1980.
15. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339: 61–68, 1998.
16. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351: 1521–1531, 2010.
17. Matsumura T, Kato T, Sugiyama N, Tasaka-Fujita M, Murayama A, Masaki T, Wakita T, Imawari M. 25-Hydroxyvitamin D3 suppresses hepatitis C virus production. Hepatology 56: 1231–1239, 2012.
18. Petta S, Camma’ C, Scazzone C, Tripodo C, Di Marco V, Bono A, Cabibi D, Licata G, Porcasi R, Marchesini G, Craxí A. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 51: 1158–1167, 2010.
19. Plum LA, Deluca HF. The functional metabolism and molecular biology of vitamin D action. In: Vitamin D: Physiology, Molecular Biology and Clinical Applications (2nd ed.), edited by Holick MF. Totowa, NJ: Humana, 2009.
20. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122: 1303-1313, 2002.
21. Ramirez AM, Wongtrakool C, Welch T, Steinmeyer A, Zügel U, Roman J. Vitamin D inhibition of pro-fibrotic effects of transformation growth factor ß1 in lung fibroblasts and epithelial cells. J Steroid Biochem Mol Biol 118: 142-150, 2010.
22. Rhee EJ, Kim MK, Park SE, Park CY, Baek KH, Lee WY, Kang MI, Park SW, Kim SW, Oh KW. High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome. Endocrine [Epub ahead of print] 2013.
23. Rocket DC. Translating an understanding of the pathogenesis of hepatic fibrosis to noval therapies. Clin Gastro Hepat 11: 224-231, 2013.
24. Scott-Conner CH, Grogan JB. The pathophysiology of biliary obstruction and its effect on phagocytic and immune function. J Surg Res 57: 316-336, 1994.
25. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 7: 3382-3393, 2006.
26. Tan X, Li Y, Liu Y. Therapeutic role and potential mechanism of active vitamin D in renal interstitial fibrosis. J Steroid Biochem Mol Biol 103: 491-496, 2007.
27. Yin Y, Yu Z, Xia M, Luo X, Lu X, Ling W. Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism. Eur J Clin Invest 42: 1189-1196, 2012.
28. Zhang Y, Kong J, Deb DK, Chang A, Li YC. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. Am Soc Nephrol 21: 966-973, 2010.
29. Zimmermann H, Blaser H, Zimmermann A, Reichen J. Effect of development on the functional and histological changes induced by bile-duct ligation in the rat. J Hepatol 20: 231-239, 1994.